Table 1 Baseline clinical and genetic characteristics of 87 core binding factor acute myeloid leukemia patients enrolled in this study.
No. (%) | CBF-AML | RUNX1-RUNX1T1 | CBFB-MYH11 | P |
|---|---|---|---|---|
Number of patients | 87 | 62 | 25 | Â |
Age, median years (range) | 44 (16–85) | 43 (16–85) | 47 (20–68) | 0.55 |
Gender | ||||
Male | 50 (57) | 37 (60) | 13 (52) | 0.68 |
Female | 37 (43) | 25 (40) | 12 (48) | Â |
WBC, × 109/L, median (range) | 16.9 (1.0–201.8) | 10.4 (1.0–201.8) | 40.1 (2.7–163.3) | 0.52 |
Mutations at baseline | ||||
KIT | 34 (39) | 28 (45) | 6 (24) | 0.11 |
D816 | 19 (22) | 16 (26) | 3 (12) | 0.26 |
N822 | 13 (15) | 13 (21) | 0 | 0.02 |
RAS | 36 (41) | 19 (31) | 17 (68) |  < 0.01 |
NRAS | 29 (33) | 16 (26) | 13 (52) | 0.04 |
KRAS | 11 (13) | 5 (8) | 6 (24) | 0.10 |
ASXL2 | 12 (14) | 12 (19) | 0 | 0.03 |
Remission induction therapy | 76 (87) | 51 (82) | 25 (100) | 0.17 |
Achievement of CR, n = 76 | 73/76 (96) | 49/51 (96) | 24/25 (96) | 1.00 |
Relapse, n = 73 | 19/73 (26) | 13/49 (27) | 6/24 (25) | 1.00 |
Death | 28 (37) | 25 (40) | 10 (40) | 1.00 |
